- Home
- IMMX vs BCSF Comparison
IMMX vs BCSF Comparison
Compare IMMX & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMMX | BCSF |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.8M | 838.7M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IMMX | BCSF |
|---|---|---|
| Price | $9.44 | $10.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $24.30 | $12.63 |
| AVG Volume (30 Days) | ★ 1.4M | 529.0K |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 17.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $39.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $10.53 |
| 52 Week High | $15.10 | $14.70 |
Technical Indicators
Market Signals| Indicator | IMMX | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 28.76 |
| Support Level | $7.96 | N/A |
| Resistance Level | $10.40 | $11.35 |
| Average True Range (ATR) | 0.76 | 0.21 |
| MACD | -0.23 | -0.01 |
| Stochastic Oscillator | 11.55 | 14.63 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.